FDA approves first 4-in-1 flu vaccine
February 29, 2012 in Medications
Federal health officials have approved the first vaccine that protects against four strains of the common flu, offering one additional layer of protection against the influenza virus that affects millions each year.
The FluMist Quadrivalent vaccine from AstraZeneca's MedImmune unit protects against two strains of influenza A and two strains of influenza B. The Food and Drug Administration approved the spray-based vaccine for people ages 2 to 49.
Previously all vaccines contained two strains of influenza A and one strain of influenza B, chosen annually by medical experts based on their potential to spread the virus. Having an extra strain of influenza B increases the likelihood that the vaccine will protect against illness, the FDA said in a statement.
Similar to the previously approved FluMist, the new vaccine is a nasal spray that delivers weakened strains of the virus.
"Illness caused by Influenza B virus affects children, particularly young and school-aged, more than any other population," said Dr. Karen Midthun, M.D., director of the FDA's biologics center.
The severity of illness and death due to flu varies widely from season to season. Between 1976 and 2007, flu-related deaths have ranged from an estimated low of about 3,000 to a high of about 49,000 people, according to the FDA.
©2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
-
FDA approves 2006 strain of flu vaccine
Aug 03, 2006 |
not rated yet |
0
-
Building a better flu vaccine: Add second strain of influenza B
Apr 06, 2010 |
not rated yet |
0
-
Study: Flu shot better than nasal spray in adults
Sep 23, 2009 |
not rated yet |
0
-
NIH experts describe influenza vaccines of the future
Nov 17, 2010 |
not rated yet |
0
-
Flu vaccine not associated with reduced hospitalizations or outpatient visits among young children
Oct 06, 2008 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
How can there be a term called "intestinal metaplasia" of stomach
22 hours ago
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013
-
If you became brain-dead, would you want them to pull the plug?
May 17, 2013
-
MRI bill question
May 15, 2013
-
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013
-
Alcohol and acetaminophen
May 13, 2013
- More from Physics Forums - Medical Sciences
More news stories
New sleeping pill poised to hit US markets
An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.
Medications
10 hours ago |
4 / 5 (4) |
0
Global recommendations on child medicine
Transparent information on the evidence supporting global recommendations on paediatric medicines should be easily accessible in order to help policy makers decides on what drugs to include in their national drug lists, according ...
Medications
11 hours ago |
not rated yet |
0
Analgesics prescribed more heavily to women than to men, study finds
Regardless of pain, social class or age, a woman is more likely to be prescribed pain-relieving drugs. A study published in Gaceta Sanitaria (Spanish health scientific journal) affirms that this phenomenon is inf ...
Medications
19 hours ago |
not rated yet |
0
Breakup of physician, drug company relationship could improve health care, cut cost
A new report suggests that improved health care and significant reductions in drug costs might be attained by breaking up the age-old relationship between physicians and drug company representatives who promote the newest, ...
Medications
May 20, 2013 |
5 / 5 (1) |
0
FDA has safety concerns on Merck insomnia drug
Federal health regulators say an experimental insomnia drug from Merck can help patients fall asleep, but it also carries worrisome side effects, including daytime drowsiness and suicidal thinking.
Medications
May 20, 2013 |
not rated yet |
0
Phthalates: Study links chemicals widely found in plastics, processed food to elevated blood pressure in children, teens
Plastic additives known as phthalates (pronounced THAL-ates) are odorless, colorless and just about everywhere: They turn up in flooring, plastic cups, beach balls, plastic wrap, intravenous tubing and—according to the ...
If you can remember it, you can remember it wrong
(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...
B vitamins could delay dementia
(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...
Insight into the dazzling impact of insulin in cells
Australian scientists have charted the path of insulin action in cells in precise detail like never before. This provides a comprehensive blueprint for understanding what goes wrong in diabetes.
Reducing caloric intake delays nerve cell loss
Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...
Antidepressant reduces stress-induced heart condition
A drug commonly used to treat depression and anxiety may improve a stress-related heart condition in people with stable coronary heart disease, according to researchers at Duke Medicine.
